Long-term efficacy of etanercept for psoriasis in daily practice

British Journal of Dermatology

Volumn 166, Issue 2, 2012, Pages 445-447

  Van Lumig P P M ^a   Driessen, R J B ^a   Boezeman, J B M ^a   Van De Kerkhof, P C M ^a   De Jong, E M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ETANERCEPT; ETRETIN; FUMARIC ACID; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PSORALEN;

ADULT; AGED; CLINICAL PRACTICE; COHORT ANALYSIS; DISEASE REGISTRY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; LETTER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PUVA; TREATMENT DURATION; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION;

ADULT; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; LONG-TERM CARE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84856211590     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10584.x     Document Type: Letter

References (10)

1. Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM,. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009; 160: 670-5.
2. Brunasso AM, Puntoni M, Salvini C, et al. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients. Acta Derm Venereol (Stockh) 2011; 91: 44-9.
3. Warren RB, Brown BC, Lavery D, et al. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol 2009; 160: 162-9.
4. Papoutsaki M, Talamonti M, Giunta A, et al. The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab. Dermatology 2010; 221 (Suppl. 1): 43-7.
5. Driessen RJ, Berends MA, Boezeman JB, et al. Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome. Br J Dermatol 2008; 158: 1098-106.
6. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-32.
7. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22.
8. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-12.
9. de Groot M, Appelman M, Spuls PI, et al. Initial experience with routine administration of etanercept in psoriasis. Br J Dermatol 2006; 155: 808-14.
10. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-26.